XL
XLO.O
—
NASDAQ
Biotechnology & Life-Science Tools
Xlo.O
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
54,1M USD
P/E
—
EV / Rev
0,3x
Div yield
—
Op margin
—
ROE
-207,5 %
Net margin
—
Debt / equity
0,09
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$8,52
Open
$8,47
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
XLO.O operates in the healthcare diagnostics industry, providing products and services related to medical research and biotechnology.
Business. XLO.O operates in the healthcare diagnostics industry, providing products and services related to medical research and biotechnology.
Classification99 %
SectorHealth Care
Industry groupBiotechnology & Life-Science Tools
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target20,00
Analyst recommendations
1 analysts · consensus BuyBuy1
Hold0
Sell0
12-month price target
20,00
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
1 analysts · indicative
Ownership→
Morgan Stanley Smith Barney LLC
largest disclosed fund holder
Profitability→
-207,5 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to XLO.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
XLO.O operates in the healthcare diagnostics industry, providing products and services related to medical research and biotechnology.
Classification99 %
SectorHealth Care
Industry groupBiotechnology & Life-Science Tools
AI synthesis
GENERATEDThe company's capital structure is characterized by a low debt-to-equity ratio of 0.09, indicating a conservative approach to leverage. With $44.7 million in cash and equivalents and $24.1 million in total liabilities, the firm maintains a strong liquidity position, as reflected in a current ratio of 3.02. The price-to-book ratio of 1.43 suggests that the market values the company slightly above its book value, while the price-to-tangible-book ratio is identical, indicating no significant intangible asset premium.
Profitability metrics reveal a challenging financial position. The company reported a net loss of $76.4 million and an operating loss of $79.1 million, resulting in a negative return on equity of -2.07 and a negative return on assets of -1.25. These figures fall significantly below the industry norms for profitability and returns, highlighting a need for operational improvements or strategic shifts to enhance performance.
Geographic and segment exposure data is not available in the provided information, but the company's revenue concentration and segment-specific performance remain undisclosed. This lack of detail limits the ability to assess the diversification of its revenue streams or the contribution of individual business segments to overall performance.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided. The operating cash flow of -$68.6 million and free cash flow of -$74.9 million indicate a cash outflow, which could constrain the company's ability to invest in growth opportunities or meet obligations without external financing.
Risk factors include the company's negative net income and operating income, which could affect its ability to sustain operations and meet financial obligations. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. However, the negative cash flows and operating losses suggest potential long-term sustainability concerns.
Recent events and filings do not show any significant developments that would impact the company's financial position or strategic direction. The absence of recent major events or disclosures implies a stable but potentially stagnant operational environment.
Key takeaways
- XLO.O has a strong liquidity position with a current ratio of 3.02 and $44.7 million in cash and equivalents.
- The company is experiencing significant financial losses, with a net loss of $76.4 million and an operating loss of $79.1 million.
- The company's return on equity and return on assets are negative, indicating poor profitability.
- The company's capital structure is conservative, with a low debt-to-equity ratio of 0.09.
- Analysts have a strong buy recommendation for XLO.O, with a mean price target of $20.00.
Bull / Bear case
analysis pipeline— missing data
In focus — financials by report
Annual
ANNUALFiled 2026-03-23
FY 2026 · Full-year highlights
Revenue $43.8M, +589,9% YoY; Operating income +30,7% YoY.
Revenue$43.8M+589,9 % YoY
Operating income-$42.0M+30,7 % YoY
Net income-$35.0M+39,8 % YoY
Free cash flow-$34.0M+39,9 % YoY
EPS—
Operating cash flow-$5.0M+72,8 % YoY
Financials
Income statement
Revenue$43.8M
Gross profit—
Operating income-$42.0M
Net income-$35.0M
Margins
Gross margin—
Operating margin-95.9%
Net margin-80.1%
FCF margin-77.7%
Balance sheet
Total assets$154.7M
Total liabilities$119.4M
Total equity$35.3M
Cash & equivalents$137.5M
Long-term debt$0.00
Cash flow
Operating cash flow-$5.0M
CapEx-$518.0k
Free cash flow-$34.0M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue $43.8M, +589,9% YoY
- ▍Operating income +30,7% YoY
- ▍Net income +39,8% YoY
- ▍Free cash flow +39,9% YoY
- ▍Net margin -80.1%
ANNUALFiled 2025-03-11
FY 2025 · Full-year highlights
Revenue $6.3M; Operating income +23,4% YoY.
Revenue$6.3M
Operating income-$60.6M+23,4 % YoY
Net income-$58.2M+23,8 % YoY
Free cash flow-$56.6M+24,5 % YoY
EPS—
Operating cash flow-$18.4M+73,2 % YoY
Financials
Income statement
Revenue$6.3M
Gross profit—
Operating income-$60.6M
Net income-$58.2M
Margins
Gross margin—
Operating margin-954.9%
Net margin-918.0%
FCF margin-892.6%
Balance sheet
Total assets$71.1M
Total liabilities$53.5M
Total equity$17.6M
Cash & equivalents$55.3M
Long-term debt$0.00
Cash flow
Operating cash flow-$18.4M
CapEx-$36.0k
Free cash flow-$56.6M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue $6.3M
- ▍Operating income +23,4% YoY
- ▍Net income +23,8% YoY
- ▍Free cash flow +24,5% YoY
- ▍Net margin -918.0%
ANNUALFiled 2024-04-01
FY 2024 · Full-year highlights
Operating income -$79.1M.
Revenue—
Operating income-$79.1M
Net income-$76.4M
Free cash flow-$75.0M
EPS—
Operating cash flow-$68.6M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$79.1M
Net income-$76.4M
Balance sheet
Total assets$60.9M
Total liabilities$24.1M
Total equity$36.8M
Cash & equivalents$44.7M
Long-term debt$3.4M
Cash flow
Operating cash flow-$68.6M
CapEx-$486.0k
Free cash flow-$75.0M
SBC—
Highlights
- ▍Operating income -$79.1M
Valuation FY
Market price
$9,05
Market cap
$52.7M
Enterprise valueⓘ
$11.4M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
0.3x
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
1.4x
P / Tangible bookⓘ
1.4x
Tangible book
$36.8M
Net cashⓘ
$41.3M
Current ratioⓘ
3.0
Debt / equityⓘ
0.1
ROAⓘ
-1.3%
ROEⓘ
-2.1%
Cash conversionⓘ
90.0%
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
Peer comparison8 peers · vs XLO · multiples and returns
IQ
IQV—
Iqvia Holdings Inc
$181,94
30,9B USDP/E
22,7x
— vs self
Div yield
—
— vs self
ROE
21,9 %
+229,3 vs self
CR
CRL—
Charles River Laboratories
$230,87
11,4B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-4,6 %
+202,9 vs self
ME
MEDP—
Medpace Holdings Inc
$576,00
16,7B USDP/E
34,4x
— vs self
Div yield
—
— vs self
ROE
75,4 %
+282,9 vs self
AL
ALKS—
Alkermes PLC
$49,53
8,2B USDP/E
39,8x
— vs self
Div yield
—
— vs self
ROE
8,4 %
+215,9 vs self
PI
PIII—
P3 Health Partners Inc
$10,20
73,8M USDP/E
—
— vs self
Div yield
—
— vs self
ROE
95,3 %
+302,8 vs self
OR
ORGO—
Organogenesis Holdings Inc
$2,38
306,2M USDP/E
9,0x
— vs self
Div yield
—
— vs self
ROE
8,5 %
+216,0 vs self
NA
NAGE—
Niagen Bioscience Inc
$3,53
281,1M USDP/E
17,4x
— vs self
Div yield
—
— vs self
ROE
22,7 %
+230,2 vs self
SP
SPRY—
Ars Pharmaceuticals Inc
$5,51
547,1M USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-149,9 %
+57,5 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-2,39
Predicted surprise
+0,00
Beat probability
45 %
Analysts
1
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-16 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -2,39 |
| Revenue | —no estimate | —no estimate | 27,3M USD |
| Operating income | —no estimate | —no estimate | -60,3M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution1 analysts
Strong buy1
Buy0
Hold0
Sell0
Strong sell0
12-month price target$20,00 · Median $20,00
Low $20,00High $20,00
Operating income · consensus-60,3M USD
EPS surprise
−75,3 %
reported vs consensus · miss
Revenue surprise
+60,3 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$20,00
Mean$20,00
Median$20,00
High$20,00
Spot$9,05
+121.0 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
ROE-207,5 %Bottom quartile
D/E0,09Bottom quartile
Cash Conv0,90Below median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 9 861 423 sh6 exercises · 40 grants13 insiders
- Director · Stock Option (right to buy) → Common StockAcquired 5 000 @ $7,99grant · 2026-06-11
- Director · Stock Option (right to buy) → Common StockAcquired 5 000 @ $7,99grant · 2026-06-11
- Director · Stock Option (right to buy) → Common StockAcquired 5 000 @ $7,99grant · 2026-06-11
- Director · Stock Option (right to buy) → Common StockAcquired 5 000 @ $7,99grant · 2026-06-11
- Director · Stock Option (right to buy) → Common StockAcquired 5 000 @ $7,99grant · 2026-06-11
- Director · Stock Option (right to buy) → Common StockAcquired 5 000 @ $7,99grant · 2026-06-11
- Director · Stock Option (right to buy) → Common StockAcquired 5 000 @ $7,99grant · 2026-06-11
- Director · Stock Option (right to buy) → Common StockAcquired 10 000 @ $8,40grant · 2026-04-15
- 10% owner · Prefunded Warrants (right to buy) → Common StockAcquired 3 739 000 @ $0,00purchase · 2026-02-13
- CHIEF MEDICAL OFFICER · Restricted Stock Units → Common StockDisposed 16 625exercise · 2026-01-01
- SVP, FINANCE AND ACCOUNTING · Restricted Stock Units → Common StockDisposed 5 000exercise · 2026-01-01
- Director, PRESIDENT AND CEO · Restricted Stock Units → Common StockDisposed 44 250exercise · 2026-01-01
- Chief Financial Officer · Restricted Stock Units → Common StockDisposed 19 375exercise · 2026-01-01
- Director, PRESIDENT AND CEO · Stock Option (right to buy) → Common StockAcquired 1 500 258 @ $0,84grant · 2025-12-31
- SVP, FINANCE AND ACCOUNTING · Stock Option (right to buy) → Common StockAcquired 95 221 @ $0,84grant · 2025-12-31
- CHIEF MEDICAL OFFICER · Stock Option (right to buy) → Common StockAcquired 451 885 @ $0,84grant · 2025-12-31
- Chief Financial Officer · Stock Option (right to buy) → Common StockAcquired 668 789 @ $0,84grant · 2025-12-31
- 10% owner · Prefunded Warrants (right to buy) → Common StockAcquired 13 335 000 @ $0,00exercise · 2025-11-26
- 10% owner · Series B Warrants (right to buy) → Common StockDisposed 13 335 000 @ $0,75exercise · 2025-11-26
- SVP, FINANCE AND ACCOUNTING · Stock Option (right to buy) → Common StockDisposed 55 000 @ $3,17disposition · 2025-11-21
- SVP, FINANCE AND ACCOUNTING · Stock Option (right to buy) → Common StockAcquired 20 000 @ $1,00grant · 2025-11-21
- SVP, FINANCE AND ACCOUNTING · Stock Option (right to buy) → Common StockDisposed 20 000 @ $1,08disposition · 2025-11-21
- SVP, FINANCE AND ACCOUNTING · Stock Option (right to buy) → Common StockAcquired 25 000 @ $1,00grant · 2025-11-21
- SVP, FINANCE AND ACCOUNTING · Stock Option (right to buy) → Common StockDisposed 25 000 @ $2,79disposition · 2025-11-21
- SVP, FINANCE AND ACCOUNTING · Stock Option (right to buy) → Common StockAcquired 55 000 @ $1,00grant · 2025-11-21
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Source documents
- XLO.O Market data — financials · 2026-05-30
- Xilio Therapeutics Inc Market data — analyst estimates · 2026-05-30
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
Insider activity
Net buying1 buys · 2 sellsnet $38K5 insiders · last 365d
- Director · Common StockBought 5 000 @ $8,79$44K · 2026-03-26
- SVP, FINANCE AND ACCOUNTING · Common StockSold 1 826 @ $0,64$1K · 2026-01-02
- Chief Financial Officer · Common StockSold 7 030 @ $0,64$5K · 2026-01-02
- Chief Financial Officer · Common StockOther 19 375 · 2026-01-01
- CHIEF MEDICAL OFFICER · Common StockOther 16 625 · 2026-01-01
- SVP, FINANCE AND ACCOUNTING · Common StockOther 5 000 · 2026-01-01
- Director, PRESIDENT AND CEO · Common StockOther 44 250 · 2026-01-01
Short positioning
268.2Kshares short+53.6% vs prior
4.52days to cover
59.4%short of daily vol
7.4Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
XLO.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Evidence & claims
From filings & derived data- Total assets (YoY) (2025-12-31 vs 2024-12-31): 117.6%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 100.4%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 36.0%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 30.7%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 72.8%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 39.8%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 589.9%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 72.5%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 72.5%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 1,338.9%Derived (calculated)
- Current ratio (FY 2025-12-31): 2.58xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 3.39xDerived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 148.7%Derived (calculated)
- Return on equity (FY 2025-12-31): -99.3%Derived (calculated)
- Net margin (FY 2025-12-31): -80.1%Derived (calculated)
- Return on assets (FY 2025-12-31): -22.6%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 123.3%Derived (calculated)
- Total assets (annual): USD 154.69MSEC XBRL filing
- Net income (annual): USD -35.04MSEC XBRL filing
- Shareholders' equity (annual): USD 35.27MSEC XBRL filing
- R&D expense (annual): USD 56.04MSEC XBRL filing
- Operating income (annual): USD -41.98MSEC XBRL filing
- Current liabilities (annual): USD 56.27MSEC XBRL filing
- Shares outstanding (annual): 4.53MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-11 00:00 UTCINSIDER7 insider transactions — 2026-06 7 derivative
2026-06-11INSIDERXu Yuan acquired 5.0k sh Stock Option (right to buy) — Director
2026-06-11INSIDERROSS ROBERT W. acquired 5.0k sh Stock Option (right to buy) — Director
2026-06-11INSIDERCurran Daniel J. acquired 5.0k sh Stock Option (right to buy) — Director
2026-06-11INSIDERShannon James Samuel acquired 5.0k sh Stock Option (right to buy) — Director
2026-06-11INSIDERBello Akintunde Olatokumbo acquired 5.0k sh Stock Option (right to buy) — Director
2026-06-11INSIDERBrennan Aoife acquired 5.0k sh Stock Option (right to buy) — Director
2026-06-11INSIDERBonstein Sara acquired 5.0k sh Stock Option (right to buy) — Director
2026-04-15 00:00 UTCINSIDER1 insider transaction — 2026-04 1 derivative
2026-04-15INSIDERBlanchard Cheryl R acquired 10.0k sh Stock Option (right to buy) — Director
2026-03-26 00:00 UTCINSIDER1 insider transaction — 2026-03
2026-03-26INSIDERShannon James Samuel bought 5.0k sh — Director ~$44k
2026-03-23 07:30 UTCEARNINGSAnnual results — FY 2026 Revenue USD 43.8M · Net USD -35.0M
2026-02-13 00:00 UTCINSIDER1 insider transaction — 2026-02 1 derivative
2026-02-13INSIDERGILEAD SCIENCES, INC. acquired 3.74M sh Prefunded Warrants (right to buy) — 10% owner
2026-01-02 00:00 UTCINSIDER10 insider transactions — 2026-01 4 derivative
2026-01-02INSIDERBrennan Kevin M. sold 1.8k sh — SVP, FINANCE AND ACCOUNTING ~$1k
2026-01-02INSIDERFrankenfield Christopher James sold 7.0k sh — Chief Financial Officer ~$5k
2026-01-01INSIDERFrankenfield Christopher James transacted 19.4k sh — Chief Financial Officer
2026-01-01INSIDERLuptakova Katarina transacted 16.6k sh — CHIEF MEDICAL OFFICER
2026-01-01INSIDERBrennan Kevin M. transacted 5.0k sh — SVP, FINANCE AND ACCOUNTING
2026-01-01INSIDERRusso Rene transacted 44.2k sh — Director, PRESIDENT AND CEO
2026-01-01INSIDERLuptakova Katarina disposed of 16.6k sh Restricted Stock Units — CHIEF MEDICAL OFFICER
2026-01-01INSIDERFrankenfield Christopher James disposed of 19.4k sh Restricted Stock Units — Chief Financial Officer
2026-01-01INSIDERRusso Rene disposed of 44.2k sh Restricted Stock Units — Director, PRESIDENT AND CEO
2026-01-01INSIDERBrennan Kevin M. disposed of 5.0k sh Restricted Stock Units — SVP, FINANCE AND ACCOUNTING
Showing the 40 most recent of 57 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage